Medulloblastoma drugs in development: Current leads, trials and drawbacks

Eur J Med Chem. 2021 Apr 5:215:113268. doi: 10.1016/j.ejmech.2021.113268.

Jiachen Wen ¹, M Kyle Hadden ²

Affiliations

1 Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Rd, Unit 3092, Storrs, CT, 06029-3092, United States.
2 Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Rd, Unit 3092, Storrs, CT, 06029-3092, United States. Electronic address: kyle.hadden@uconn.edu.

PMID: 33636537 DOI: 10.1016/j.ejmech.2021.113268

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor in children. Current treatment for MB includes surgical resection, radiotherapy and chemotherapy. Despite significant progress in its management, a portion of children relapse and tumor recurrence carries a poor prognosis. Based on their molecular and clinical characteristics, MB patients are clinically classified into four groups: Wnt, Hh, Group 3, and Group 4. With our increased understanding of relevant molecular pathways disrupted in MB, the development of targeted therapies for MB has also increased. Targeted drugs have shown unique privileges over traditional cytotoxic therapies in balancing efficacy and toxicity, with many of them approved and widely used clinically. The aim of this review is to present the recent progress on targeted chemotherapies for the treatment of all classes of MB.

Keywords

Chemotherapy; Hh pathway; Medulloblastoma; Molecular targeting drugs; Wnt pathway.

Name
Email *

	Sorry, but the email address you supplied was invalid.